Top

Journal of Cancer Research and Clinical Oncology

Published in:

01-10-2015 | Original Article – Clinical Oncology

Evaluation of the prognostic value and functional roles of CD44v6 in gastric cancer

Authors: Jian-Wei Xie, Peng-Chen Chen, Chao-Hui Zheng, Ping Li, Jia-Bin Wang, Jian-Xian Lin, Jun Lu, Qi-Yue Chen, Long-Long Cao, Mi Lin, Yao Lin, Chang-Ming Huang

Published in: Journal of Cancer Research and Clinical Oncology | Issue 10/2015

Abstract

Purpose

Tumor stem cell surface marker CD44v6, a member of the CD44 protein family, is causally involved in the metastasis of cancer. Little is known about the functions of CD44v6 in gastric cancer. The aim of this study was to evaluate the prognostic value of CD44v6 and investigate its functional roles.

Methods

The expression of CD44v6 in 208 primary gastric adenocarcinoma patient samples was examined using immunohistochemistry and its correlation with clinicopathological parameters, and 5-year patient survival was assessed. Two pairs of MGC-803 stable cells with either CD44v6 overexpression or knockdown were created. The effect of CD44v6 on cell proliferation, colony formation, migration and apoptosis was investigated using these two pairs of cells.

Results

Overexpression of CD44v6 was observed in all cancer cell lines. The 5-year survival rate of patients with positive CD44v6 expression is significantly worse compared to those with negative expression (38.8 vs. 73.6 %). CD44v6 and TNM stage are two independent prognostic factors of primary gastric adenocarcinoma. The risk factors for the positive CD44v6 expression are location of tumor, depth of invasion, lymph node metastasis, Lauren classification and TNM stage. In MGC-803 cells, CD44 stimulated proliferation and colony formation, antagonized oxaliplatin-induced apoptosis, but did not affect migration.

Conclusion

CD44v6 is an important prognosis marker in gastric cancer. Tissue specificity may affect the functions of CD44v6, and further work is needed to elucidate its regulation.

Afify A, Purnell P, Nguyen L (2009) Role of CD44 s and CD44v6 on human breast cancer cell adhesion, migration, and invasion. Exp Mol Pathol 86:95–100. doi:10.1016/j.yexmp.2008.12.003 CrossRefPubMed

Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF (2003) Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A 100:3983–3988. doi:10.1073/pnas.05302911000530291100 PubMedCentralCrossRefPubMed

Aruffo A, Stamenkovic I, Melnick M, Underhill CB, Seed B (1990) CD44 is the principal cell surface receptor for hyaluronate. Cell 61:1303–1313. doi:10.1016/0092-8674(90)90694-A CrossRefPubMed

Bajorath J (2000) Molecular organization, structural features, and ligand binding characteristics of CD44, a highly variable cell surface glycoprotein with multiple functions. Proteins 39:103–111. doi:10.1002/(SICI)1097-0134(20000501)39:2<103:AID-PROT1>3.0.CO;2-G CrossRefPubMed

Chen J, Li T, Liu Q, Jiao H, Yang W, Liu X, Huo Z (2014a) Clinical and prognostic significance of HIF-1alpha, PTEN, CD44v6, and survivin for gastric cancer: a meta-analysis. PLoS One 9:e91842. doi:10.1371/journal.pone.0091842PONE-D-13-38378 PubMedCentralCrossRefPubMed

Chen Y, Fu Z, Xu S, Xu Y, Xu P (2014b) The prognostic value of CD44 expression in gastric cancer: a metaanalysis. Biomed Pharmacother 68:693–697. doi:10.1016/j.biopha.2014.08.001S0753-3322(14)00095-X CrossRefPubMed

Collins AT, Berry PA, Hyde C, Stower MJ, Maitland NJ (2005) Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 65:10946–10951. doi:10.1158/0008-5472.CAN-05-2018 CrossRefPubMed

Correia M, Machado JC, Ristimaki A (2009) Basic aspects of gastric cancer. Helicobacter 14(Suppl 1):36–40. doi:10.1111/j.1523-5378.2009.00696.xHEL696 CrossRefPubMed

Dalerba P et al (2007) Phenotypic characterization of human colorectal cancer stem cells. Proc Natl Acad Sci U S A 104:10158–10163. doi:10.1073/pnas.0703478104 PubMedCentralCrossRefPubMed

Ferro A et al (2014) Worldwide trends in gastric cancer mortality (1980-2011), with predictions to 2015, and incidence by subtype. Eur J Cancer 50:1330–1344CrossRefPubMed

Kim MC, Lee HJ, Lim B, Ha KT, Kim SY, So I, Kim BJ (2014) Quercetin induces apoptosis by inhibiting MAPKs and TRPM7 channels in AGS cells. Int J Mol Med 33:1657–1663. doi:10.3892/ijmm.2014.1704 PubMed

Li C et al (2007a) Identification of pancreatic cancer stem cells. Cancer Res 67:1030–1037. doi:10.1158/0008-5472.CAN-06-2030 CrossRefPubMed

Li F, Tiede B, Massague J, Kang Y (2007b) Beyond tumorigenesis: cancer stem cells in metastasis. Cell Res 17:3–14. doi:10.1038/sj.cr.7310118 CrossRefPubMed

Lozano R et al (2012) Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 380:2095–2128. doi:10.1016/S0140-6736(12)61728-0S0140-6736(12)61728-0 CrossRefPubMed

Marhaba R, Bourouba M, Zoller M (2005) CD44v6 promotes proliferation by persisting activation of MAP kinases. Cell Signal 17:961–973. doi:10.1016/j.cellsig.2004.11.017 CrossRefPubMed

Mielgo A, van Driel M, Bloem A, Landmann L, Gunthert U (2006) A novel antiapoptotic mechanism based on interference of Fas signaling by CD44 variant isoforms. Cell Death Differ 13:465–477. doi:10.1038/sj.cdd.4401763 CrossRefPubMed

Mikami T, Saegusa M, Mitomi H, Yanagisawa N, Ichinoe M, Okayasu I (2001) Significant correlations of Ecadherin, catenin, and CD44 variant form expression with carcinoma cell differentiation and prognosis of extrahepatic bile duct carcinomas. Am J Clin Pathol 116:369–376. doi:10.1309/VV6D-3GAH-VEJM-DUJT CrossRefPubMed

Nagano O et al (2004) Cell-matrix interaction via CD44 is independently regulated by different metalloproteinases activated in response to extracellular Ca(2+) influx and PKC activation. J Cell Biol 165:893–902. doi:10.1083/jcb.200310024jcb.200310024 PubMedCentralCrossRefPubMed

Orian-Rousseau V (2010) CD44, a therapeutic target for metastasising tumours. Eur J Cancer 46:1271–1277. doi:10.1016/j.ejca.2010.02.024 CrossRefPubMed

Orian-Rousseau V, Ponta H (2015) Perspectives of CD44 targeting therapies. Arch Toxicol 89:3–14. doi:10.1007/s00204-014-1424-2 CrossRefPubMed

Schwitalla S (2014) Tumor cell plasticity: the challenge to catch a moving target. J Gastroenterol 49:618–627. doi:10.1007/s00535-014-0943-1 CrossRefPubMed

Takaishi S et al (2009) Identification of gastric cancer stem cells using the cell surface marker CD44. Stem Cells 27:1006–1020. doi:10.1002/stem.30 PubMedCentralCrossRefPubMed

Vigetti D et al (2008) Hyaluronan-CD44-ERK1/2 regulate human aortic smooth muscle cell motility during aging. J Biol Chem 283:4448–4458. doi:10.1074/jbc.M709051200 CrossRefPubMed

Xin Y, Grace A, Gallagher MM, Curran BT, Leader MB, Kay EW (2001) CD44V6 in gastric carcinoma: a marker of tumor progression. Appl Immunohistochem Mol Morphol 9:138–142PubMed

Yasui W, Kudo Y, Naka K, Fujimoto J, Ue T, Yokozaki H, Tahara E (1998) Expression of CD44 containing variant exon 9 (CD44v9) in gastric adenomas and adenocarcinomas: relation to the proliferation and progression. Int J Oncol 12:1253–1258PubMed

Zlobec I, Gunthert U, Tornillo L, Iezzi G, Baumhoer D, Terracciano L, Lugli A (2009) Systematic assessment of the prognostic impact of membranous CD44v6 protein expression in colorectal cancer. Histopathology 55:564–575. doi:10.1111/j.1365-2559.2009.03421.x CrossRefPubMed

Title: Evaluation of the prognostic value and functional roles of CD44v6 in gastric cancer
Authors: Jian-Wei Xie
Peng-Chen Chen
Chao-Hui Zheng
Ping Li
Jia-Bin Wang
Jian-Xian Lin
Jun Lu
Qi-Yue Chen
Long-Long Cao
Mi Lin
Yao Lin
Chang-Ming Huang
Publication date: 01-10-2015
Publisher: Springer Berlin Heidelberg
Published in: Journal of Cancer Research and Clinical Oncology / Issue 10/2015
Print ISSN: 0171-5216
Electronic ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-015-1964-8

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 10/2015

Prognostic impact of transcription factor Fra-1 in ER-positive breast cancer: contribution to a metastatic phenotype through modulation of tumor cell adhesive properties

Leukocyte telomere length: a novel biomarker to predict the prognosis of glioma patients

The network of epithelial–mesenchymal transition: potential new targets for tumor resistance

Height and kidney cancer risk: a meta-analysis of prospective studies

Combination of exosomes and circulating microRNAs may serve as a promising tumor marker complementary to alpha-fetoprotein for early-stage hepatocellular carcinoma diagnosis in rats

Follicular variant of papillary thyroid carcinoma (FVPTC): histological features, BRAF V600E mutation, and lymph node status

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials